https://clinicaltrials.gov/ct2/show/NCT03661125?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=07%2F30%2F2019&lupd_d=14&sort=nwst
STUDY TITLE:
SRC Inhibition as a Potential Target for Parkinson’s Disease Psychosis
DESCRIPTION:
Condition: Parkinson Disease Psychosis
Interventions: Drug: Saracatinib; Drug: Placebo Oral Tablet
Sponsors: King’s College London; AstraZeneca; King’s College Hospital NHS Trust
Recruiting
CLINICALTRIALS.GOV IDENTIFIER:
NCT03661125
FIRST POSTED:
Fri, 07 Sep 2018 12:00:00 EDT
LAST UPDATE POSTED:
08/13/19 06:58AM
STUDY LINK / URL:
https://clinicaltrials.gov/ct2/show/NCT03661125?recrs=abdef&type=Intr&cond=Parkinson+Disease&phase=0124&lupd_s=07%2F30%2F2019&lupd_d=14&sort=nwst
